D
DSGN
Design Therapeutics, Inc.
15.23
+0.24+1.60%After Hours: 15.53 +0.30 +1.97%19:30 08/24 EDT
OPEN/PREV CLOSE14.91/14.99
TODAY RANGE14.64-15.47
VOL408.65K
MARKET CAP953.12M
52 WEEK RANGE4.920-17.25
AVG VOL (3M)733.61K
% TURNOVER0.65%
TURNOVER--
P/E (TTM)-12.9013
% RANGE5.54%
EPS(TTM)-1.1805
P/E(FORWARD)-11.1304
P/B4.722
BVPS3.226
DIVIDEND--
P/S1,804.76
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP623.06M
SHARES OUTSTANDING62.58M
NEXT EARNINGS11/03-11/09
FREE FLOAT40.91M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·08/06 01:47
RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)
TipRanks·08/03 12:22
Design Therapeutics reports Q2 EPS (32c), consensus (34c)
Seeking Alpha·08/03 12:04
Design Therapeutics GAAP EPS of -$0.32 beats by $0.02
Benzinga·08/03 12:04
Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate
Dow Jones·08/03 12:00
*Design Therapeutics 2Q Loss $20.2M >DSGN
Dow Jones·08/03 12:00
Press Release: Design Therapeutics Provides -2-
Dow Jones·08/03 12:00
*Design Therapeutics 2Q Loss/Shr 32c >DSGN
Seeking Alpha·07/27 20:31
A Deeper Dive Into Design Therapeutics
Seeking Alpha·07/19 19:10
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
TipRanks·06/30 12:20
Design Therapeutics initiates patient dosing in DT-818 trial
Simply Wall St·06/27 13:25
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
Seeking Alpha·06/24 22:07
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Same Industry
Name/Symbol
Change%
Price